| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/S41417-020-00256-7 |
| P698 | PubMed publication ID | 33191402 |
| P50 | author | R Srikar | Q102063581 |
| P2093 | author name string | Reena Rajkumari | |
| K Sreedurgalakshmi | |||
| P2860 | cites work | The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP | Q24649549 |
| A comprehensive pathway map of epidermal growth factor receptor signaling | Q24672490 | ||
| Genetic alterations defining NSCLC subtypes and their therapeutic implications | Q27024615 | ||
| Novel mutant-selective EGFR kinase inhibitors against EGFR T790M | Q27658766 | ||
| Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer | Q27680966 | ||
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer | Q27851588 | ||
| Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors | Q27851633 | ||
| Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials | Q27853120 | ||
| MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor. | Q27853240 | ||
| Development and applications of CRISPR-Cas9 for genome engineering | Q28241526 | ||
| Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors | Q28272463 | ||
| The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer | Q28387975 | ||
| Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening | Q28596034 | ||
| Detection of mutations in EGFR in circulating lung-cancer cells | Q29615033 | ||
| Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer | Q29615476 | ||
| CRISPR-Cas systems for editing, regulating and targeting genomes | Q29615781 | ||
| Genome-scale CRISPR-Cas9 knockout screening in human cells | Q29616044 | ||
| Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 | Q29617043 | ||
| Genetic screens in human cells using the CRISPR-Cas9 system | Q29617411 | ||
| CRISPR-Cas9 knockin mice for genome editing and cancer modeling | Q30607892 | ||
| Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression. | Q33677872 | ||
| Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors | Q33769838 | ||
| Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer | Q33810641 | ||
| Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing | Q33829488 | ||
| EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications | Q33963199 | ||
| Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining | Q34468164 | ||
| Fas receptor-mediated apoptosis: a clinical application? | Q34495634 | ||
| Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer | Q34773458 | ||
| TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation | Q34778203 | ||
| Rapid modelling of cooperating genetic events in cancer through somatic genome editing | Q34938584 | ||
| Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library | Q35096218 | ||
| High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells | Q35143589 | ||
| Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment | Q35227986 | ||
| PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase | Q35616065 | ||
| Identification and validation of dysregulated MAPK7 (ERK5) as a novel oncogenic target in squamous cell lung and esophageal carcinoma | Q35651895 | ||
| Multiplexed barcoded CRISPR-Cas9 screening enabled by CombiGEM. | Q35920105 | ||
| Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse | Q36508976 | ||
| Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth. | Q47554878 | ||
| Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. | Q47627028 | ||
| Deactivated CRISPR Associated Protein 9 for Minor-Allele Enrichment in Cell-Free DNA. | Q47644164 | ||
| A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution. | Q48711405 | ||
| EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases | Q49089662 | ||
| The biology and management of non-small cell lung cancer | Q49826396 | ||
| Liquid Biopsy: From Basic Research to Clinical Practice | Q50163302 | ||
| In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. | Q50882019 | ||
| Application of CRISPR-Cas9 Based Genome-Wide Screening Approaches to Study Cellular Signalling Mechanisms | Q52347926 | ||
| Anti-tumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR Exon 20 Insertions | Q52430499 | ||
| In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis | Q52431419 | ||
| Specific targeting of point mutations in EGFR L858R-positive lung cancer by CRISPR/Cas9. | Q53684294 | ||
| Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming | Q54497843 | ||
| Comparison of p53 and epidermal growth factor receptor gene status between primary tumors and lymph node metastases in non-small cell lung cancers. | Q54652248 | ||
| Receptor Tyrosine Kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors. | Q54976676 | ||
| SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. | Q54977899 | ||
| Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants. | Q55289701 | ||
| A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC. | Q55339149 | ||
| Pooled Lentiviral CRISPR-Cas9 Screens for Functional Genomics in Mammalian Cells | Q57454453 | ||
| Modulation of mutant KrasG12D-driven lung tumorigenesis in vivo by gain or loss of PCDH7 function | Q58585653 | ||
| The continuously evolving CRISPR barcoding toolbox | Q58699403 | ||
| Selective targeting of KRAS oncogenic alleles by CRISPR/Cas9 inhibits proliferation of cancer cells | Q58796049 | ||
| Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach | Q59793918 | ||
| Up-Regulated FGFR1 Expression as a Mediator of Intrinsic TKI Resistance in EGFR-Mutated NSCLC | Q60044591 | ||
| Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries | Q60142201 | ||
| Lung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibition | Q64060566 | ||
| Targeting exon 20 insertion mutations in non-small cell lung cancer | Q64118764 | ||
| Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer | Q64236786 | ||
| Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing | Q64386928 | ||
| EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer. | Q64949390 | ||
| Fas-induced apoptosis is mediated by activation of a Ras and Rac protein-regulated signaling pathway | Q71574095 | ||
| A CRISPR Test for Rapidly and Sensitively Detecting Circulating EGFR Mutations | Q89860704 | ||
| Functional Gene Knockout of NRF2 Increases Chemosensitivity of Human Lung Cancer A549 Cells In Vitro and in a Xenograft Mouse Model | Q90055403 | ||
| Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer | Q90139206 | ||
| Highly efficient DSB-free base editing for streptomycetes with CRISPR-BEST | Q90240255 | ||
| Simple in Vivo Gene Editing via Direct Self-Assembly of Cas9 Ribonucleoprotein Complexes for Cancer Treatment | Q90363341 | ||
| Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer | Q90697707 | ||
| The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients | Q90974072 | ||
| The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity | Q91013772 | ||
| EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies | Q91083904 | ||
| CRISPR-Cas: a tool for cancer research and therapeutics | Q91142488 | ||
| In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma | Q91343630 | ||
| LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma | Q91650846 | ||
| Recent advances in aerosol gene delivery systems using non-viral vectors for lung cancer therapy | Q91696659 | ||
| Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors | Q91840546 | ||
| Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer | Q91937343 | ||
| Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer | Q92035698 | ||
| Cause-and-Effect relationship between FGFR1 expression and epithelial-mesenchymal transition in EGFR-mutated non-small cell lung cancer cells | Q92086302 | ||
| STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort | Q92091040 | ||
| Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers | Q92111772 | ||
| Liquid Biopsy by Next-Generation Sequencing: a Multimodality Test for Management of Cancer | Q92191367 | ||
| The AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC | Q92214297 | ||
| CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer | Q92217305 | ||
| Specificity Assessment of CRISPR Genome Editing of Oncogenic EGFR Point Mutation with Single-Base Differences | Q92256739 | ||
| Stimulation of CRISPR-mediated homology-directed repair by an engineered RAD18 variant | Q92296048 | ||
| Applications of CRISPR/Cas9 Technology in the Treatment of Lung Cancer | Q92681575 | ||
| AGK-BRAF is associated with distant metastasis and younger age in pediatric papillary thyroid carcinoma | Q92695843 | ||
| CX Chemokine Receptor 7 Contributes to Survival of KRAS-Mutant Non-Small Cell Lung Cancer upon Loss of Epidermal Growth Factor Receptor | Q92758220 | ||
| Translatable gene therapy for lung cancer using Crispr CAS9-an exploratory review | Q92920001 | ||
| Epigenetic CRISPR screens identify Npm1 as a therapeutic vulnerability in non-small cell lung cancer | Q97535525 | ||
| Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway | Q36970403 | ||
| EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. | Q37021792 | ||
| Structure-based view of epidermal growth factor receptor regulation | Q37197992 | ||
| EGFR family: structure physiology signalling and therapeutic targets | Q37272623 | ||
| LHX6 acts as a novel potential tumour suppressor with epigenetic inactivation in lung cancer | Q37299656 | ||
| The distribution of BRAF gene fusions in solid tumors and response to targeted therapy | Q37308973 | ||
| EGFR T790M mutation: a double role in lung cancer cell survival? | Q37354807 | ||
| MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors | Q37399525 | ||
| Nucleophosmin sets a threshold for p53 response to UV radiation | Q37424634 | ||
| CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A. | Q37649874 | ||
| CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer | Q38614582 | ||
| IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells | Q38707122 | ||
| A genetic interaction analysis identifies cancer drivers that modify EGFR dependency | Q38717620 | ||
| Applications of the CRISPR/Cas9 system in murine cancer modeling | Q38858314 | ||
| Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains | Q38876767 | ||
| Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. | Q38895804 | ||
| DNA sequencing and CRISPR-Cas9 gene editing for target validation in mammalian cells | Q38984711 | ||
| DrugTargetSeqR: a genomics- and CRISPR-Cas9-based method to analyze drug targets | Q38984714 | ||
| Evaluating TBK1 as a therapeutic target in cancers with activated IRF3. | Q39002218 | ||
| MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer | Q39044325 | ||
| Cornerstones of CRISPR-Cas in drug discovery and therapy | Q39051110 | ||
| In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges | Q39163867 | ||
| Translating cancer epigenomics into the clinic: focus on lung cancer | Q39394558 | ||
| ERK5/BMK1 is indispensable for optimal colony-stimulating factor 1 (CSF-1)-induced proliferation in macrophages in a Src-dependent fashion. | Q40005436 | ||
| A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. | Q40289611 | ||
| Rapidly evolving homing CRISPR barcodes | Q40441230 | ||
| CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations. | Q41194695 | ||
| Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer | Q41225190 | ||
| Targeted nanoconjugate co-delivering siRNA and tyrosine kinase inhibitor to KRAS mutant NSCLC dissociates GAB1-SHP2 post oncogene knockdown | Q41729089 | ||
| Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology | Q41747565 | ||
| Genetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-mediated apoptosis | Q41775168 | ||
| KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer | Q41952724 | ||
| Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. | Q41992348 | ||
| In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. | Q42183080 | ||
| The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer | Q42337044 | ||
| Evaluation of digital PCR for detecting low-level EGFR mutations in advanced lung adenocarcinoma patients: a cross-platform comparison study | Q42366577 | ||
| CRISPR-Cas9-based target validation for p53-reactivating model compounds. | Q42577802 | ||
| Drug for an 'undruggable' protein | Q42734596 | ||
| Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer. | Q44951464 | ||
| Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer | Q46512789 | ||
| CUT-PCR: CRISPR-mediated, ultrasensitive detection of target DNA using PCR. | Q47162594 | ||
| Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage | Q47328087 | ||
| CRISPR/Cas9 library screening for drug target discovery | Q47329392 | ||
| P921 | main subject | CRISPR | Q412563 |
| non-small-cell lung carcinoma | Q3658562 | ||
| P577 | publication date | 2020-11-15 | |
| P1433 | published in | Cancer Gene Therapy | Q15763088 |
| P1476 | title | CRISPR-Cas deployment in non-small cell lung cancer for target screening, validations, and discoveries |
Search more.